Becton, Dickinson heads into its fiscal fourth-quarter report with the market having already paid for last quarter's turnaround story. The shares have climbed roughly 11% since the July-quarter beat-and-raise while the S&P 500 went nowhere. That sets up a harder question for November 5. Can BD show that the acceleration it delivered in its first full quarter as a slimmed-down company survives a period that management itself warned would look slower?

Wall Street expects adjusted earnings of $4.06 per share, about 2.5% above the $3.96 reported a year ago, on revenue of roughly $5.12 billion. The headline revenue decline of about 13% is mostly an accounting artifact of the portfolio separation tied to the Waters transaction, so it says little about underlying demand. The modest EPS growth is the more honest signal. This is a quarter of incremental progress, not a breakout. Management's full-year guidance of $12.62 to $12.72 per share has been lifted at each of the last two reports, and the low end has risen from $12.35 at the start of the year. The full-year consensus of $12.53 still sits below the bottom of that range. That gap suggests some analysts have not fully bought into the raises. It also means simply landing inside guidance would push estimates higher.

The operational test centers on how much growth survives the Alaris comparison. Revenue for the continuing business grew 4.4% last quarter, up from about 2.5% in each of the first two quarters. Management pointed to double-digit gains in biologics and GLP-1 drug delivery, advanced patient monitoring, PureWick, and tissue regeneration. It also flagged that the drag from lapping last year's Alaris infusion pump remediation shipments doubles to about 200 basis points this quarter. A step down in reported growth is therefore expected. If organic growth outside Alaris, China vaccines and the other contained headwinds holds near high single digits, the inflection narrative stays intact. Evidence of continued Alaris share gains beyond the 200 basis points cited year to date, and of GLP-1 pen agreements moving past roughly 100, would strengthen it further.

Margins are the bigger swing factor. Adjusted operating margin ran 21.2%, 24.2% and 24.9% across the first three quarters, and tariffs cost about 110 basis points in the third. BD has held its full-year target near 25%. Hitting it requires the fourth quarter to be the strongest margin quarter of the year. Any slippage would signal that tariffs and elevated resin costs are eating into the earnings leverage the bull case depends on. Free cash flow, already up 45% year to date at $1.7 billion, offers some cushion if earnings quality comes into question.

The forward conversation may matter as much as the quarter itself. Management has framed fiscal 2027 as another year of low-single-digit revenue growth with only modest EPS leverage. It cited the continuing Alaris grow-over and a conservative stance on oil-linked input costs. Formal guidance, and any color ahead of the promised Investor Day, will show whether newer launches can begin to offset those drags. Those include the Liberty stent graft in Europe, the holmium laser entry into endourology, and the EMS semaglutide pen deal in Brazil. Leadership changes in Medical Essentials and Interventional add a minor element of execution risk.

Sentiment remains net bearish but has eased from the prior quarter, while the stock trades well above its 200-day moving average. At about $195, it sits within 3% of its post-earnings high of $200.47, so it is effectively testing a breakout. That is a demanding perch. The core question is whether BD can deliver a roughly 25% margin quarter and a credible 2027 outlook despite a softer reported top line. If it can, the acceleration story becomes a durability story. If margins fall short, the recent rally leaves little room for disappointment.